2002
DOI: 10.1101/sqb.2002.67.519
|View full text |Cite
|
Sign up to set email alerts
|

Cellular Therapies for Myocardial Infarct Repair

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
9
0

Year Published

2004
2004
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 29 publications
(9 citation statements)
references
References 2 publications
0
9
0
Order By: Relevance
“…[18][19][20] Azarnoush et al 21 reported that more than 90% of autologous skeletal myoblasts underwent apoptosis or necrosis at 24 h after transplantation. The retention of endothelial progenitor cells has been quantified <5% in the infarcted heart at 96 h after transplantation.…”
Section: Introductionmentioning
confidence: 99%
“…[18][19][20] Azarnoush et al 21 reported that more than 90% of autologous skeletal myoblasts underwent apoptosis or necrosis at 24 h after transplantation. The retention of endothelial progenitor cells has been quantified <5% in the infarcted heart at 96 h after transplantation.…”
Section: Introductionmentioning
confidence: 99%
“…Given the limited supply of transplant hearts in the face of a large population of patients with end-stage heart disease, much attention has recently been directed at cell transplantation strategies as an alternative strategy to ameliorate cardiac injury. [1][2][3] As currently envisioned for human therapeutic application, a suitable myogenic cell type from either an autologous or appropriately matched allogeneic source is delivered to the infarcted zone in an attempt to repopulate the lost myocardium. A number of different cell types have been considered for such therapies, including skeletal myoblasts, 4 -6 bone marrow-derived hematopoietic stem cells, [7][8][9][10] mesenchymal stem cells, [11][12][13][14] intrinsic cardiac stem cells, 15,16 and embryonic stem cells (ESCs).…”
mentioning
confidence: 99%
“…Moreover, current therapeutic modalities attenuate disease progression without contributing significantly to myocardial repair (16). In this regard, an alternative approach to conventional strategies is emerging with advances in the manipulation of nonterminally differentiated cells that maintain the potential to form cardiomyocytes and, thus, the propensity to replace diseased myocardium (27,28,30,36,42).…”
mentioning
confidence: 99%